NEUP · Neuphoria Therapeutics Inc.

The operating loss of $1.2M versus $12.0M profit reflects the direct impact of management's October 2025 decision to discontinue or pause all R&D activities, resulting in no incremental research and development expenses during the quarter, including for non-BNC210 candidates. Product candidates in later clinical stages typically drive higher costs due to larger, longer trials, so this pause meaningfully reduced spending pressure. R&D costs are expensed as incurred unless qualifying for capitalization, aligning with the observed swing to losses as prior-year profitability benefited from milestone timing.

General and administrative expenses contributed to the margin compression to -8.1%, as the company navigated a restructuring transition. Cost-cutting measures effective December 31, 2025, included terminating facility leases—writing off right-of-use assets and derecognizing liabilities—and ending substantially all employee contracts. These actions, while adding transitional friction, are expected to decrease G&A in future periods during the operational pause and strategic review. Management's current operating plan, which it believes is implementable, supports these projections, though assumptions carry risks of earlier capital depletion.

Net income loss of $505K followed the operating shortfall, with diluted EPS at -$0.09. Operating cash flow marked a sharp turnaround to $3.7M from -$11.7M, driven by working capital changes and non-cash adjustments post-restructuring. Financing activities continued via the at-the-market facility for share issuances net of costs. This cash generation validates cost controls amid paused R&D and headcount reductions, extending operational flexibility. Projections of capital needs rest on the operating plan, but ordinary course increases in expenses remain possible if strategic matters evolve differently.